CVSA Stock Forecast & Price Target

Covista is well-positioned for growth with its favorable program mix, primarily in the online university business and a strong focus on healthcare programs which are outperforming enrollment trends. While there are potential risks such as pressure on student acquisition from AI search, the company's mix of healthcare programs and exposure to AI disruption should mitigate these risks. The company's financials are solid with increasing revenue and adjusted EPS projections, and its fixed cost structure should lead to attractive incremental margins. Overall, we rate CVSA as a Buy with expectations of continued growth and potential for multiple expansion.

Covista is a healthcare educator that has multiple accredited institutions and generates the majority of its revenue from its Walden segment. While Covista has consistently outperformed its peers, the company's premium multiple is already reflected in its stock price. Furthermore, potential disruptions from AI-driven student acquisition and new loan caps could present challenges for the company in the next 12 months. Chamberlain's recent return to enrollment growth could provide some positive sentiment, but uncertainties remain given the changing industry landscape and leadership changes within the company.